Abstract
Aim:
To investigate the fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom in vitro and in vivo.
Methods:
125I-labeled human plasma clot lysis was measured in vitro and rabbit carotid artery thrombosis was as an in vivo model.
Results:
In vitro, urokinase (UK) at 25, 35, 40, 45, 60 kU/L and FIIa at 0.08, 0.23, 0.4, 0.5, and 0.7 g/L resulted an equivalent clot lysis (20%, 40%, 50%, 60%, and 80%). UK at 25-60 kU/L induced 27.3%±3.6%, 35.2%±2.3%, 39.3%±2.4%, 44.2%±4.6%, and 51.1%±1.2% fibrinogen degradation. But FIIaat 0.08–0.7 g/L induced 95.4%±0.3%, >95.6%, >95.6%, >95.6%, >95.6% fibrinogen degradation respectively. In vivo, UK 40 kU/kg and FIIa 1.0 mg/kg reduced the weight of residual thrombus to 9.0±2.5 mg and 7.8±3.5 mg compared with negative control group (30.0±5.4 mg). But the fibrinogen degradation rate after UK 40 kU/kg and FIIa 1.0 mg/kg treatment was 24.4%±6.2% and 4.1%±7.8%, respectively (P < 0.05, n=6). The order of the lysis speed after UK 125 kU/L treatment was platelet poor plasma (PPP) clots>the whole blood clots>platelet rich plasma (PRP) clots. The sequence for FIIa 0.4 g/L was PRP>PPP>whole blood clots.
Conclusion:
At the same percentage of clot lysis, FIIa degraded more fibrinogen than UK did in vitro but less fibrinogen than UK did in vivo. The order of the lysis speed was PPP>whole blood clots>PRP clots for UK and PRP>PPP>whole blood clots for FIIa.
Similar content being viewed by others
Article PDF
References
Verstraete M, Lijnen HR, Collen D . Thrombolytic agents in development. Drugs 1995; 50: 29–42.
Collen D, Verstraete M . Systematic thrombolytic therapy of acute myocardial infarction. Circulation 1983; 68: 462–5.
Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11.
Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, et al. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222–30.
Liang XX, Chen JS, Zhou YN, Qiu PX, Yan GM . Purification and biochemical characterization of FIIa, a fibrinolytic enzyme from Agkistrodon acutus venom. Toxicon 2001; 39: 1133–9.
Chen JS, Liang XX, Qiu PX, Yan GM . Thrombolysis effect with FIIa from Agkistrodon acutus venom in different thrombosis model. Acta Pharmacol Sin 2001; 22: 420–2.
Chen JS, Liang LG, Sun JJ . The pharmacology characterizations of fibrinolytic fraction II from five-pace snake venom. Chin Pharmacol Bull 1993; 9: 22–5.
Gurewich V, Pannell R, Louis S, Kelley P, Robert L, Suddith RL, et al. Effective and fibrin-specific clot lysis by a zymogen precursor from a study in vitro and in tow animal species. J Clin Invest 1984, 73: 1731–9.
Wang QC, Xu YL, Liu GF . A simple rabbit carotid thrombus model and the fibrinolytic effect of acutinase. Chin Pharmacol Bull 1993, 9: 228–9.
Datta G, Dong A, Witt J, Tu AT . Biochemical characterization of basilase, a fibrinolytic enzyme from Crotalus basiliscus basiliscus. Arch Biochem Biophys 1995, 317: 365–73.
Gurewich V, Pannell R . A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Throm Res 1986, 44: 217–28.
Wang QQ, Chen JS, Liang XX, Qiu PX, Wang YW, Yan GM . Hemorrhagic activity and mechanism of FIIa, a fibrinolytic enzyme from Agkistrodon acutus venom. Acta Pharmacol Sin 2004; 25: 514–21.
Manning MC . Sequence analysis of fibrolase, a fibrinolytic metalloproteinase from Agkistrodon contortrix contortrix. Toxin 1995; 33: 1189–200.
Huang TF, Chang MC, Peng HC, Teng CM . A novel alphatype fibrinogenase from Agkistrodon rhodostoma snake venom. Biophim Biophys Acta 1992; 1160: 262–8.
Sugihara H, Mori N, Nikai T, Kishida M, Akagi M . Comparative study of three proteinases from the venom of the Chinese hahu snake (Trimeresurus mucrosquamatus). Comp Biochem Physiol B 1985; 82: 29–35.
Estêvão-costa MI, Diniz CR, Magalhães A, Markland FS, Sanchezâ EF . Thromb Res 2000; 99: 363–76.
Kamiguti AS, Hay CRM, Zuzel M . Inhibition of collagen-induced platelet aggregation as the result of cleavage at α2β1–integrin by the snake venom metalloproteinase jararhagin. Biochem J 1996; 320: 635–C41.
Liu CZ, Huang TF . Crovidisin, a collagen-binding protein isolated from snake venom of Crotalus viridid, prevents platelet-collagen interaction. Arch Biochem Biophys 1997; 337: 291–9.
Perutelli P . Disintegrins: potent inhibitors of platelet aggregation. Recent Prog Med 1995; 86: 168–74.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by Guangdong Science and Technology Commission, (No 203059).
Rights and permissions
About this article
Cite this article
Wang, Yw., Liang, Xx., Chen, Js. et al. Fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom. Acta Pharmacol Sin 26, 691–695 (2005). https://doi.org/10.1111/j.1745-7254.2005.00099.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00099.x
Keywords
This article is cited by
-
Recombinant production of fibrinogenase IV from Agkistrodon acutus venom and its preliminary evaluation
Applied Microbiology and Biotechnology (2006)